Milea Timbergen

227 Table 1. (continued) Score 1. Score 2. / additional interests Ref. N (N- PROM) Location T Outcome Pre-treatment Outcome Post-treatment functional impairment 34 106 AS SG ARTx RTx ST NA 0-1 T: 23% functional impairment: moderate n = 13, major n = 2; 2 T: 56% functional impairment: moderate n=8, major n = 7; ≥ 3 T: 74% functional impairment: moderate n = 7, major n = 10 pain; functional; impairment cosmetic outcome 35 12 (7) EA CT n=7 pain; n=7 functional limitation; n=3 cosmesis n = 6 pain relief; n = 3 partial improvement of function, n = 4 restore of normal function; N = 2 improvement of cosmetic outcome. a Desmoid-type fibromatosis and soft tissue sarcoma combined, reported outcome for subgroup of DTF, b At most recent reported follow-up, c Group A: radiological progressive disease (PD), Group B: symptomatic deterioration and Group C: radiologically PD and symptomatic deterioration AS: all sites; EA: extra-abdominal; AW: abdominal wall; IA: intra-abdominal; LE: lower extremities; HN: head and neck; UE: upper extremities ACT: adjuvant chemo therapy; ARTx: adjuvant radiotherapy; BT: brachytherapy; CA: cryoablation; CT: chemotherapy; DASH, Disabilities of the Arm, Shoulder and Hand; Enneking / MSTS score, Enneking score adopted by the Musculoskeletal Tumour Society; EORTC QLQ-C30, The European Organisation for Research and Treatment of Cancer quality of life questionnaire C30; GSI: γ-secretase inhibitor; MDAS, MD Anderson symptom Inventory; MRgFUS: magnetic resonance-guided focused ultrasound; N, number of patients; NA, Not applicable; N-PROM, Number of patients with DTF and available patient reported outcomes; NRS, Numerical Rating Scale; NSG: no-surgery; PD, Progressive disease; PROM, Patient Reported Outcome Measurement; SG: surgery; Refs, reference; RTx: radiotherapy; T, treatment; TESS, Toronto Extremity Salvage score 8